Changes in the Cystic Fibrosis Airway Microbiome in Response to CFTR Modulator Therapy.

Buqing Yi, Alexander H. Dalpke, Sébastien Boutin

Abstract

The development of CFTR modulator therapies significantly changed the treatment scheme of people with cystic fibrosis. However, CFTR modulator therapy is still a life-long treatment, which is not able to correct the genetic defect and cure the disease. Therefore, it becomes crucial to understand the effects of such modulation of CFTR function on the airway physiology, especially on airway infections and inflammation that are currently the major life-limiting factors in people with cystic fibrosis. In this context, understanding the dynamics of airway microbiome changes in response to modulator therapy plays an essential role in developing strategies for managing airway infections. Whether and how the newly available therapies affect the airway microbiome is still at the beginning of being deciphered. We present here a brief review summarizing the latest information about microbiome alterations in light of modern cystic fibrosis modulator therapy.
Original languageEnglish
JournalFrontiers in Cellular and Infection Microbiology
Volume11
Pages (from-to)548613
Number of pages1
ISSN2235-2988
DOIs
Publication statusPublished - 2021
Externally publishedYes

Research Areas and Centers

  • Academic Focus: Center for Infection and Inflammation Research (ZIEL)

DFG Research Classification Scheme

  • 204-03 Medical Microbiology and Mycology, Hygiene, Molecular Infection Biology

Cite this